9 November 2015
EMA/PDCO/677901/2015
Procedure Management and Committees Support Division

Paediatric Committee (PDCO)

Draft agenda for the meeting on 11-13 November 2015

Chair: Dirk Mentzer – Vice-Chair: Koenraad Norga

11 November 2015, 08:30- 19:00, room 3A

12 November 2015, 08:30- 19:00, room 3A

13 November 2015, 08:30- 13:00, room 3A

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the PDCO Committee meeting reports (after the PDCO Opinion is adopted), and on the Opinions and decisions on paediatric investigation plans webpage (after the EMA Decision is issued).

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom
Telephone +44 (0)20 3660 6000 **Facsimile** +44 (0)20 3660 5555
Send a question via our website www.ema.europa.eu/contact

Table of contents

1. Introductions

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the PDCO plenary session to be held 11-13 November 2015. See November 2015 PDCO minutes (to be published post December 2015 PDCO meeting).

1.2. Adoption of agenda

PDCO agenda for 11-13 November 2015.

1.3. Adoption of the minutes

PDCO minutes for 7-9 October 2015.

2. Opinions

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

2.1. Opinions on Products

2.2. Opinions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

2.3. Opinions on Re-examinations

2.4. Finalisation and adoption of opinions

3. Discussion of applications

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Discussions on Products D90-D60-D30

3.2. Discussions on Compliance Check

The following compliance checks have been put up for discussion and the members of the PDCO have been invited to comment on issues of possible non-compliance

3.3. Discussions on Modification of an Agreed Paediatric Investigation Plan

4. Nominations

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. List of letters of intent received for submission of applications with start of procedure February 2016 for Nomination of Rapporteur and Peer reviewer

Action: For adoption

4.2. Nomination of Rapporteur for requests of confirmation on the applicability of the EMA decision on class waiver.

Action: For adoption

4.3. Nominations for other activities

4.3.1. Nomination of PDCO Chair to represent the committee at the workshop 'Successes and Challenges of Performing Long-Term Paediatric Safety Studies' organised by the Food and Drug Administration (FDA) on 13-14 April 2016

Action: For adoption

4.3.2. Ethical considerations for clinical trials on medicinal products conducted with the paediatric population: call for expression of interest from PDCO members

Action: For adoption

5. Scientific Advice Working Party (SAWP) and Paediatric Committee (PDCO) Interaction

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6. Discussion on the applicability of class waivers

Disclosure of information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Discussions on the applicability of class waiver for products

7. Discussion on the inclusion of an indication within a condition in an agreed PIP/waiver

7.1. Discussion on the possibility to include an indication within a condition in an agreed PIP/waiver

None

8. Annual reports on deferrals

8.1.1. Brentuximab vedotin / Monoclonal antibody against human CD30 covalently linked t...– Adcetris - EMEA-000980-PIP01-10-M03

Takeda Pharma A/S

Difficulties progressing the PIP? Yes

Action: For information

8.1.2. Cannabidiol / Delta-9-tetrahydrocannabinol – Sativex - EMEA-000181-PIP01-08

GW Pharma Ltd

Difficulties progressing the PIP? No

Action: For information

8.1.3. Golimumab – Simponi - EMEA-000265-PIP02-11-M01

Janssen Biologics B.V.

Difficulties progressing the PIP? No

Action: For information

8.1.4. Regadenoson – Rapiscan - EMEA-000410-PIP01-08-M01

Rapidscan Pharma Solutions (RPS) EU Ltd

Difficulties progressing the PIP? No

Action: For information

8.1.5. Saxagliptin – Onglyza- EMEA-000200-PIP01-08-M04

AstraZeneca AB

Difficulties progressing the PIP? Yes

Action: For information

8.1.6. Certolizumab Pegol – Cimzia - EMEA-001071-PIP02-12-M01

UCB Pharma SA

Difficulties progressing the PIP? No

Action: For information

8.1.7. Tiotropium bromide (monohydrate) – Spiriva Respimat, Spiriva - EMEA-000035-PIP02-09-M02

Boehringer Ingelheim International GmBH

Difficulties progressing the PIP? No

Action: For information

8.1.8. Tadalafil - Cialis, Adcirca - EMEA-000452-PIP02-10-M03

Eli Lilly and Company Ltd

Difficulties progressing the PIP? Yes

Action: For information

8.1.9. Sildenafil citrate - Revatio- EMEA-000671-PIP01-09-M07

Pfizer Limited

Difficulties progressing the PIP? No

Action: For information

8.1.10. Cobicistat- Tybost - EMEA-000969-PIP01-10-M03

Gilead Sciences International Limited

Difficulties progressing the PIP? Yes

Action: For information

8.1.11. Idelalisib - Zydelig - EMEA-001350-PIP02-13-M01

Gilead Sciences International Limited

Difficulties progressing the PIP? No

Action: For information

8.1.12. Telaprevir - Incivo - EMEA-000196-PIP01-08-M03

Janssen Infectious Diseases BVBA

Difficulties progressing the PIP? Yes

Action: For information

9. Organisational, regulatory and methodological matters

9.1. Mandate and organisation of the PDCO

9.1.1. PDCO members' training 26 January 2016

Action: For information

9.2. Coordination with EMA Scientific Committees or CMDh-v

9.2.1. Committee for Medicinal Products for Human Use (CHMP)

Action: For information

9.2.2. Fusafungine (NAP), for nasal and oral solution

Applicant: Les Laboratoires Servier, various

PDCO expert: Koenraad Norga

Scope: Review of the benefit-risk balance following notification by Italy of a referral under Article 31 of Directive 2001/83/EC, based on pharmacovigilance data

Action: For adoption of PDCO answers to PRAC list of questions

9.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

9.3.1. Non-clinical Working Group: D30 Products identified

PDCO member: Jacqueline Carleer

Action: For information

9.3.2. Formulation Working Group

PDCO member: Brian Aylward

Action: For information

9.3.3. Non-clinical Working Group

PDCO member: Jacqueline Carleer

Delegation attending the PDCO

Action: For information

9.3.4. European Medicines Agency Human Scientific Committees' Working Party with Patients' and Consumers' Organisations (PCWP) Work Plan for 2016

Action: For adoption

9.3.5. European Medicines Agency Human Scientific Committees' Working Party with Healthcare Professionals' Organisations (HCPWP) Work Plan for 2016

Action: For adoption

9.3.6. Report from PDCO-COMP Strategic Review and Learning Meeting held in Bonn on 14-16 October 2015

PDCO Chair: Dirk Mentzer; PDCO member: Birka Lehmann

Action: For information

9.3.7. Guideline on Clinical investigation of recombinant and Human plasma-derived factor IX products (replacing EMA/CHMP/BPWP/144552/2009)

Action: For information

9.3.8. Guideline on Clinical investigation of recombinant and human plasma-derived factor VIII products (Rev. 1)

Action: For information

9.4. Cooperation within the EU regulatory network

9.4.1. European Network of Paediatric Research (Enpr) - European Medicines Agency (EMA)

None

9.4.2. Results of survey project 'Questionnaire to children about taking medicines and participation in clinical trials'

Expert: Sofia Nordenmalm

Action: For information

9.5. Cooperation with International Regulators

9.5.1. Overview of extrapolation activities at EU and ICH level

PDCO Chair: Dirk Mentzer

Action: For discussion

9.6. Contacts of the PDCO with external parties and interaction with the Interested Parties to the Committee

None

9.7. PDCO work plan

9.7.1. Draft PDCO Work Plan 2016

Action: For discussion

9.8. Planning and reporting

None

9.9. PDCO ORGAM

9.9.1. PDCO ORGAM Agenda for 4 November 2015

Action: For information

9.9.2. PDCO ORGAM Draft Minutes for 4 November 2015

Action: For adoption

10. Any other business

None

11. Breakout sessions

11.1.1. Paediatric oncology

Action: For discussion on Wednesday, 19:00 - 19:30, room 3L

11.1.2. Deferrals in paediatric only development

Action: For discussion on Wednesday, 19:00 - 19:30, room 3J

11.1.3. Neonatology

Action: For discussion on Wednesday, 19:00 - 19:30, room 3H

11.1.4. White Paper Drafting Group

Action: For discussion on Thursday, 19:00 - 19:30, room 3H

12. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Paediatric investigation plan (PIP) (section 2.1 Opinion on PIPs and section 3.1 Discussions on PIPs)
A paediatric investigation plan (PIP) is a development plan aimed at ensuring that the necessary data are obtained through studies in children, when it is safe to do so, to support the authorisation of a medicine for children. Pharmaceutical companies submit proposals for PIPs to the European Medicines Agency's Paediatric Committee (PDCO). This Committee is responsible for agreeing or refusing the plan.

Compliance checks (section 2.2 Opinions on Compliance check, section 3.2 Discussions on Compliance check)
A compliance check may be necessary before any application for marketing authorisation (even for an adult indication) can be considered valid, if there was no deferral for at least one of the studies agreed in the PIP, or after the due date of initiation or completion of a study/measure. The same applies to some regulatory applications for authorised products, as described above.

Modification of an Agreed Paediatric Investigation Plan (section 2.3 Opinions on Modification of an agreed PIP, section 3.3 Discussions on Modification of an agreed PIP)
The development plan for a medicine can be modified at a later stage as knowledge increases. Modifications can also be made if the applicant encounters such difficulties with the implementation of a PIP, which render it unworkable or no longer appropriate.
In some cases, studies can be deferred until after the studies in adults have been conducted. This ensures that research in children is done only when it is safe and ethical to do so. Even when studies are deferred, the PIP will include details of the paediatric studies and their timelines.

Class waiver (section 6 Discussion on the applicability of class waiver)
As some diseases do not affect children (for example Parkinson's disease), the development of medicines for these diseases should not be performed in children. In these cases, a PIP is not required and it will be waived**.** For more information on the classes of diseases subject to waivers, see class waivers.

Annual reports on deferrals (section 8)
If the medicinal product is approved in the EU, annual reports on the deferred measures in the PIP must be submitted to the Agency.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/